{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:05:44Z","timestamp":1791655544720,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2110,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1093\/annonc\/mdt541","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T05:40:50Z","timestamp":1387431650000},"page":"472-476","source":"Crossref","is-referenced-by-count":33,"title":["A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma"],"prefix":"10.1016","volume":"25","author":[{"given":"N.","family":"Shinohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nonomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt541_bb0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1442-2042.2012.02962.x","article-title":"Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan","volume":"19","author":"Wada","year":"2012","journal-title":"Int J Urol"},{"key":"10.1093\/annonc\/mdt541_bb0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.critrevonc.2010.03.006","article-title":"Experience with sorafenib and adverse event management","volume":"78","author":"Bellmunt","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdt541_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt541_bb0025","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/jjco\/hym095","article-title":"Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma","volume":"37","author":"Akaza","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdt541_bb0030","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejon.2011.05.001","article-title":"Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment for renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group","volume":"16","author":"Edmonds","year":"2012","journal-title":"Eur J Oncol Nurs"},{"key":"10.1093\/annonc\/mdt541_bb0035","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1093\/annonc\/mdt541_bb0040","first-page":"520","article-title":"Evaluation of a new pressure ulcer preventive dressing containing ceramide 2 with low frictional outer layer","volume":"59","author":"Nakagami","year":"2007","journal-title":"J AdvNurs"},{"key":"10.1093\/annonc\/mdt541_bb0045","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/02841860701765675","article-title":"Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis","volume":"47","author":"Chu","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdt541_bb0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1346-8138.2010.01059.x","article-title":"Sorafenib-associated hand-foot syndrome in Japanese patients","volume":"38","author":"Iijima","year":"2011","journal-title":"J Dermatol"},{"key":"10.1093\/annonc\/mdt541_bb0055","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00387600","article-title":"Expression of c-kit ligand in human keratinocytes","volume":"286","author":"Morita","year":"1994","journal-title":"Arch Dermatol Res"},{"key":"10.1093\/annonc\/mdt541_bb0060","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/1078-0432.CCR-08-1141","article-title":"Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy","volume":"15","author":"Azad","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt541_bb0065","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000258880","article-title":"Hand-foot syndrome (hand-foot skin reaction, palmer-planter erythrodysesthesia): focus on sorafenib and sunitinib","volume":"77","author":"Lipworth","year":"2009","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdt541_bb0070","first-page":"492","article-title":"Etiologic factors in pressure sores: an experimental model","volume":"62","author":"Daniel","year":"1981","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1093\/annonc\/mdt541_bb0075","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt541_bb0080","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdt541_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.suponc.2010.12.007","article-title":"Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse","volume":"9","author":"Manchen","year":"2011","journal-title":"J Support Oncol"},{"key":"10.1093\/annonc\/mdt541_bb0090","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10637-011-9652-2","article-title":"The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis","volume":"30","author":"Balagula","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdt541_bb0095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncr.27705","article-title":"Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma","volume":"119","author":"Lee","year":"2013","journal-title":"Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419364592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419364592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/2\/472\/475779\/mdt541.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:35:58Z","timestamp":1624520158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419364592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0923753419364592"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt541","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}